Resilience of Antibiotic Usage and Vital Signs in COVID-19 Patients: A Post-Pandemic Analysis in Pakistan
DOI:
https://doi.org/10.53560/PPASA(61-4)683Keywords:
Antibiotic Levels, Vital Signs, Survival and Mortality, Post COVID Patients AnalysisAbstract
COVID-19 has had a profound global impact, wreaking havoc on economies and causing a significant loss of lives. Pakistan has also faced severe consequences from the pandemic. To combat the virus, antibiotics such as Azithromycin, Ceftriaxone, Cefixime, Clarithromycin, Levofloxacin, Moxifloxacin, Meropenem, Tazobactam, Tienam, and Vancomycin have been administered to COVID-19 patients. Various vital signs such as temperature, respiratory rate, oxygen saturation, pulse rate, and blood pressure have been closely linked to the symptoms of COVID-19. This study examines the impact of antibiotic usage and vital signs on the survival and mortality of COVID-19 patients using a dataset collected from four major hospitals in Pakistan. The analytical approach includes descriptive analysis, a t-test, and a chi-square test of independence. The originality of this research lies in its comprehensive exploration of the relationship between specific antibiotics and the monitoring of vital signs in the context of COVID-19. It offers a systematic analysis of existing information to derive meaningful insights. Azithromycin emerged as the predominant antibiotic used to treat COVID-19 patients in Pakistan, with other antibiotics showing varying usage patterns. Strong, significant associations were identified between Azithromycin, Tazobactam (Tanzo), and the binary response variable (died/alive). Regarding vital signs, significant relationships were observed for patient age, systolic blood pressure, and diastolic blood pressure when compared to the response variable. This study's findings underscore the importance of Azithromycin and Tazobactam in COVID-19 treatment and highlight the role of vital signs in predicting patient outcomes.
References
J.I.F. Salluh, T. Lisboa, and F.A. Bozza. Challenges for the care delivery for critically ill COVID-19 patients in developing countries: The Brazilian perspective. Critical Care 24: 593 (2020).
D.M. Morens, J.K. Taubenberger, and A.S. Fauci. A centenary tale of two pandemics: The 1918 influenza pandemic and COVID-19, part I. American Journal of Public Health 111(6): 1086-1094 (2021).
S.A. Lee and R.A. Neimeyer. Pandemic Grief Scale: A screening tool for dysfunctional grief due to a COVID-19 loss. Death Studies 46(1): 14-24 (2022).
A. Waris, U.K. Atta, M. Ali, A. Asmat, and A. Baset. COVID-19 outbreak: current scenario of Pakistan. New Microbes and New Infections 35: 100681 (2020).
M. Atif and I. Malik. Why is Pakistan vulnerable to COVID‐19 associated morbidity and mortality? A scoping review. The International Journal of Health Planning and Management 35(5): 1041-1054 (2020).
O.D. Williams. COVID-19 and private health: market and governance failure. Development 63(2): 181-190 (2020).
S. Arshad, P. Kilgore, Z.S. Chaudhry, G. Jacobsen, D.D. Wang, K. Huitsing, I. Brar, J.G. Alangaden, M.S. Ramesh, J.E. McKinnon, W.O. Neill, and M. Zervos. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases 97: 396-403 (2020).
C. Miranda, V. Silva, R. Capita, C. Alonso-Calleja, G. Igrejas, and P. Poeta. Implications of antibiotics use during the COVID-19 pandemic: present and future. Journal of Antimicrobial Chemotherapy 75(12): 3413-3416 (2020).
P. Gautret, J. Lagier, P. Parola, V.T. Hoang, L. Meddeb, M. Mailhe, B. Doudier, J. Courjon, V. Giordanengo, V.E. Vieira, H.T. Dupont, S. Honore, P. Colson, E. Chabriere, B.L. Scola, J.M. Rolain, P. Brouqui, and D. Raoult. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents 56(1): 105949 (2020).
D. Echeverria-Esnal, C. Martin-Ontiyuelo, M.E. Navarrete-Rouco, M.D.A. Cusco, O. Ferrandez, J.P. Horcajada, and S. Grau. Azithromycin in the treatment of COVID-19: A review. Expert Review of Anti-Infective Therapy 19(2): 147-163 (2021).
B. Gonzalez-Zorn. Antibiotic use in the COVID-19 crisis in Spain. Clinical Microbiology and Infection 27(4): 646-647 (2020).
B.J. Langford, M. So, S. Raybardhan, V. Leung, J.P.R. Soucy, D. Westwood, N. Daneman, and D.R. MacFadden. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clinical Microbiology and Infection 27(4): 520-531 (2021).
M.H. Hussein, E.A. Toraih, A.S. Attia, N. Burley, A.D. Zhang, J. Roos, A. Houghton, N. Aniemeka, M. Omar, M. Aboueisha, M.A. Shama, J. Duchesne, and E. Kandi. Asthma in COVID-19 patients: An extra chain fitting around the neck. Respiratory Medicine 175: 106205 (2020).
R. Irizarry, D. Sukato, R. Kollmar, S. Schild, J. Silverman, K. Sundaram, S. Stephenson, and M. Stewart. Seizures induce obstructive apnea in DBA/2J audiogenic seizure‐prone mice: Lifesaving impact of tracheal implants. Epilepsia 61(2): 13-16 (2020).
A.D.B. Estrada, J.C. Parra, E.F. Carracedo, A.M. Miguez, A.R. Martínez, E.M. Rubio, M.R. Rivas, P. Agudo, F.A. Fernandez, V.E. Perez, M.L.T. Martinez, A.C. Vieitez, P.M.P. Fontan, M. Bustamante, S.J. Freire, I.O. Bermudez, A. Artero, J.O. Sierra, M.A. Manrique, H.F.J.C. Sanchez, V.C. Vento, G.M. Garcia, P.C. Morais, J.M.C. Rojo, and J.M.N. Cortes. Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. BMC Infectious Diseases 21: 1144 (2021).
F.D.S.D. Fiol, C.D.C Bergamaschi, I.P.D. Andrade Jr, L.C. Lopes, M.T. Silva, and S. Barberato-Filho. Consumption trends of antibiotics in Brazil during the COVID-19 pandemic. Frontiers in Pharmacology 13: 844818 (2022).
H. Akhtar, S. Akhtar, F.U. Rahman, M. Afridi, S. Khalid, S. Ali, N. Akhtar, Y.S. Khader, H. Ahmad, and M.M. Khan. An overview of the treatment options used for the management of COVID-19 in Pakistan: Retrospective observational study. JMIR Public Health and Surveillance 7(5): e28594 (2021).
A. Mansoor, M.T. Khan, A. Hussain, E. Mansoor, A. Gul, and A. Saleem. Comparison of different treatment strategies combating COVID-19 in Pakistan. Pakistan Armed Forces Medical Journal 72(5): 1752-1756 (2022).
F. Saeed, M. Zubair, M. Jawad, F. Ullah, M.N. Uddin, U. Siddique, A. Wahab, and A. Rizwan. Epidemiological, clinical characteristics and possible treatment of coronavirus disease (Covid-19) during early situation in population of district Karak, Khyber Pakhtunkhwa, Pakistan. Pak-Euro Journal of Medical and Life Sciences 4(4): 337-346 (2021).
M.Z. Alvi, M. Sattar, F.A. Cheema, U.A. Awan, M.N. Aftab, Z.A. Shah, and M.S. Afzal. COVID-19 and emergence of antimicrobial resistance: a most neglected aspect of health emergency in Pakistan. Diabetes & Metabolic Syndrome 15(4): 102179 (2021).
Z.U. Mustafa, M.S. Saleem, M.N. Ikram, M. Salman, S.A. Butt, S. Khan, B. Godman, and R.A. Seaton. Co-infections and antimicrobial use among hospitalized COVID-19 patients in Punjab, Pakistan: findings from a multicenter, point prevalence survey. Pathogens and Global Health 116(7): 421-427 (2022).
M. Farooqui, Z. Iqbal, A. Sadiq, A. Raziq, M.S. Alshammari, Q. Iqbal, S. Haider, and F. Saleem. Hospital pharmacists’ viewpoint on quality use of antibiotics and resistance: A qualitative exploration from a tertiary care hospital of Quetta city, Pakistan. Antibiotics 12(8): 1343 (2023).
B. Gul, M. Sana, A. Saleem, Z.U. Mustafa, M. Salman, Y.H. Khan, T.H. Mallhi, T.M. Sono, J.C. Meyer, and B.B. Godman. Antimicrobial dispensing practices during COVID-19 and the implications for Pakistan. Antibiotics 12(6): 1018 (2023).
Z.U. Haq, M. Shahzad, M.I. Khattak, S. Fazid, N. Ullah, A. Sherin, N.U. Haq, A. Azhar, U. farooq, N.M. Darwesh, M. Asim, M.A. Gohar, A. Ashraf, S.I. Khattak, S. Ashraf, S. Akbar, M. Fawad, M.I. Khan, A. Amanullah, M. Siddiq, and A.H. Aamir. Clinical characteristics, mortality and associated risk factors in COVID-19 patients reported in ten major hospitals of Khyber Pakhtunkhwa, Pakistan. Journal of Ayub Medical College Abbottabad 32(Suppl. 1): 633–639 (2020).
G. Aksel, M.M. Islam, A. Algın, S.E. Eroglu, G.B. Yaşar, E. Ademoglu, and U.C. Dolek. Early predictors of mortality for moderate to severely ill patients with Covid-19. The American Journal of Emergency Medicine 45: 290-296 (2021).
M.A. Qureshi, K.U Toori, and R.M. Ahmed. Predictors of Mortality in COVID-19 patients: An observational study. Pakistan Journal of Medical Sciences 39(1): 241-247 (2023).
T.H. Jeong, C. Pak, M. Ock, S.H. Lee, J.S. Son, and Y.j. Jeon. Real asymptomatic SARS-CoV-2 infection might be rare: importance of careful interviews and follow-up. Journal of Korean Medical Science 35(37): e333 (2020).
